Spoken Alpha
Lite Strategy, Inc.
Lite Strategy, Inc. develops cancer therapies and holds oral drug candidates voruciclib (a CDK9 inhibitor) and zandelisib (a PI3Kδ inhibitor) in preclinical stages.
Lite Strategy, Inc is a Healthcare company operating in Biotechnology with a $35.4M market cap.
Most recent reported earnings: Q4 FY2026 (Sep 24, 2026).
Behavioral analysis
Disclosures
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add LITS, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LITS.
$ curl https://api.spokenalpha.com/v1/companies/LITSFAQ
Spoken Alpha indexes LITS's earnings call transcripts at https://spokenalpha.com/companies/LITS. Each call links to attributed speakers and parsed analyst Q&A.
Lite Strategy, Inc. (LITS) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 2026-09-24 | — | — | — | — | — | — | EODHD |
| Q3 FY2026 | 2026-05-28 | $-0.66 | — | — | $0 | — | — | EODHD |
| Q2 FY2026 | 2026-02-16 | $-0.82 | — | — | $0 | — | — | EODHD |
| Q1 FY2026 | 2025-11-13 | $-0.12 | — | — | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-09-25 | $-0.40 | $0.00 | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-05-12 | $-0.39 | — | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-02-11 | $-0.40 | $-1.33 | +69.9% | $0 | — | — | EODHD |
| Q1 FY2025 | 2024-11-12 | $-1.20 | — | — | $0 | — | — | EODHD |
| Q4 FY2024 | 2024-09-18 | $-1.13 | $-1.40 | +19.3% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-05-08 | $-1.37 | $-1.26 | -8.7% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-02-12 | $-1.66 | $-1.27 | -30.7% | — | — | — | EODHD |
| Q1 FY2024 | 2023-11-08 | $8.46 | $-1.79 | +100.0% | — | — | — | EODHD |
| Q4 FY2023 | 2023-08-30 | $-1.51 | $-0.13 | -100.0% | — | — | — | EODHD |
| Q3 FY2023 | 2023-05-10 | $-2.32 | $-2.80 | +17.1% | — | — | — | EODHD |
| Q2 FY2023 | 2023-02-08 | $1.46 | $-4.60 | +100.0% | — | — | — | EODHD |
| Q1 FY2023 | 2022-11-13 | $-2.66 | $-4.40 | +39.6% | — | — | — | EODHD |
| Q4 FY2022 | 2022-09-07 | $-0.21 | $-0.19 | -9.1% | — | — | — | EODHD |
| Q3 FY2022 | 2022-05-22 | $-3.23 | $-3.27 | +1.2% | — | — | — | EODHD |
| Q2 FY2022 | 2022-02-09 | $-1.78 | $-4.40 | +59.6% | — | — | — | EODHD |
| Q1 FY2022 | 2021-11-09 | $-2.20 | $-2.30 | +4.3% | — | — | — | EODHD |
Source: EODHD. LITS reported actuals as published; sparse fields render as —.